Small Cap Feast
Small Cap Feast – 01 March 2019
Dish of the Day:
United Oil & Gas (UOG) has moved to AIM from the Main Market (standard).
United Oil & Gas (UOG) has moved to AIM from the Main Market (standard).
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
DWF, a global legal business, expects to raise primary gross proceeds of approximately £75m. Due March
US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 20 March
Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m.
Alpha Growth (ALGW.L) 1.6p £2.08m
The financial services specialist in the growing Senior Life Settlement (SLS) asset class, announced the acquisition of Colva Insurance Services Corp.
Colva is a specialist actuarial service provider to the SLS industry and has a number of key clients, primarily based in the US.
Alpha will acquire the entire share capital of Colva for a total consideration of £77,727 in shares.
The major shareholder of Colva is Rajiv Rebello, who founded Colva in order to use his first hand actuarial and life insurance expertise to minimize premium payments and maximize returns for life insurance and life settlement investors. Rajiv is a Fellow of the Society of Actuaries (FSA) and prior to Colva worked on AIG’s 4,000+ policy life settlement portfolio with $18bn in face. He will join Alpha as Chief Actuary and Director of Investment Analytics.
Future (FUTR.L) 740p £561.64m
The global platform for specialist media, announced the acquisition of MoNa Mobile Nations, a leading global digital publisher focused on consumer electronics and based in the US .
The initial cash consideration is $55m with a further $5m to be satisfied through the issue to the vendors of 615,166 new ordinary shares.
Further variable deferred consideration up to a total value of $60m based on 2020 targets. The deferred consideration is expected to be split equally between cash and the issuance of new shares in Future, although Future retains the right to pay the full balance in cash.
Mobile Nations achieved revenue of $16.4m and EBITDA of $8.2m in FYDec18 – Organic revenue growth of 31% and EBITDA growth of 52% yoy. Expected to be earnings enhancing in the current financial year and materially earnings enhancing in the first full year following completion.
MaxCyte (MXCT.L) 177.5p £91.12m
The global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.
“We’re excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte’s versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics.”
PetroTal (PTAL.L) 14.50p £77.97m
The BN 95-2-2-2XD oil development well commenced drilling operations on Feb 26, 2019. The well is to be completed as a producer in the Vivian formation in the northern portion of the Bretaña structure, progressing the first phase of development of the Bretaña oilfield. The well will be directionally drilled to 3,040 meters total depth and will take up to 45 days to drill and complete. The well is the first in a program of three new producers designed to boost production to over 5,000 barrels of oil per day by mid-year 2019.
In addition to the primary objective of completing the well as an oil producer in the Vivian Formation, the drilling plan includes a deeper exploration section to test a secondary objective in the underlying Chonta formation. The Chonta formation has been a secondary producer of oil in the fields north of Bretaña.
Vertu Motors (VTU.L) 37p £145.28m
FYFeb19 update from the UK automotive retailer.
“The Board expects the trading performance for the year ended 28 Feb 2019 to be in line with current market expectations. Whilst the outlook remains uncertain, the Group continues to be very well positioned to take full advantage of tougher markets which will, as has been the case in previous sector downturns, provide opportunities. We have a strong balance sheet, underpinned by a property-rich asset base with low levels of debt, a clear focus upon capital allocation and we have an outstanding and stable team.”
Group revenues +5.2% (lfl 1.4%), Service revenues +14.2% (lfl 7.4%). Used retail vehicle volumes +6.2%. New down 4.8%. Fleet down 29.1%.
Omega Diagnostics (ODX.L) 13.25p £16.82m
The medical diagnostics company focused on allergy, food intolerance and infectious disease, announced the appointment of Jeremy Millard as NED to the Board with immediate effect, after a thorough search process.
Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a NED and chairman of the audit committee of AIM-listed Idox plc and a NED of AIM-listed Ilika Plc.
IXICO (IXI.L) 31.5p £14.03m
“The data analytics company delivering insights in neuroscience, announced that it has been chosen as a small-to-medium enterprise (SME) partner in the newly established London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. With the official public launch having taken place yesterday (28 Feb), the centre has been established as part of the UK Government’s Industrial Strategy Challenge Fund.
Led by King’s College London, the new Centre will develop and train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data to provide tools for clinicians to speed up and improve diagnosis and care across a number of patient pathways including dementia, heart failure and cancer.”
Sirius Real Estate (SRE.L) 60p £1,238.54m
The operator of branded business parks providing conventional space and flexible workspace in Germany, has formed a real estate investment joint venture with clients represented by AXA Investment Managers – Real Assets in which AXA IM – Real Assets, acting on behalf of its clients, will own a 65% interest and Sirius will own the balance of 35%.
AXA IM – Real Assets will acquire, on behalf of its clients, from Sirius a 65% stake in five single asset SPVs through which it currently owns two business parks located in Berlin and one in each of Mainz, Nurnberg and Bayreuth. The implied property value of €168m equates to a gross yield for the portfolio of 6.2% Total cash commitment from AXA amounts to €43.9m. The transaction is expected to generate net cash proceeds of more than €70m for Sirius.
Octagonal (OCT.L) 1.75p £9.95m
“Further to the announcement dated 8 Jan 2019, Octagonal Plc announced that it has had formal confirmation from the Securities and Futures Commission of Hong Kong that it has granted GIS FS (HK) Ltd, a wholly owned of the Company’s wholly owned subsidiary GIS, the licence to carry on regulated activity and have further approved John Gunn and Stephen Marcon as RO’s (Responsible Officers). The Company will now commence operations in Hong Kong including the provision of Type 1 regulated activity (ies) for professional clients under the Securities and Futures Ordinance (SFO). This Type 1 regulated activity(ies) includes the provision of dealing in securities, stock options, and bonds, but also includes the provision of providing other additional GIS core services such as safe custody and trade settlement.”
AFH Financial (AFHP.L) 340p £142.81m
AGM Statement from the leading financial planning led wealth management firm.
“2018 was a period of exceptional growth for AFH as we continued to deliver on our vision of becoming the leading financial planning-led wealth manager in the UK. To this end, we produced our fifth year of improved profitability since joining AIM in 2014 with record revenues of £50.7m, up 51% from 2017, an increase in EPS of 43%, an underlying EBITDA margin of 21% and a 50% increase in dividend per share to 6p, from the previous financial year. “16 acquisitions were completed in the year.”
“Looking to the current financial year, trading remains in line with expectations. We have continued the momentum of 2018 into the first four months of our new financial year with four acquisitions already completed.”
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.